Physician profile
Dan E Steinfink
NPI 1144295296
$8,357.85
in general payments reported to CMS, 2019-2025
36 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $58.16 · 2021: $2,044 · 2022: $1,493 · 2023: $1,556 · 2024: $1,708 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,394 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,394.33 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,090.96 | 2021-2025 | Vraylar |
| Validus Pharmaceuticals LLC | $957.87 | 2021-2024 | Equetro |
| Otsuka America Pharmaceutical, INC. | $956.44 | 2021-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $644.91 | 2020-2025 | Trintellix |
| Lundbeck LLC | $465.43 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $425.35 | 2022-2025 | Caplyta |
| Corium, LLC | $399.81 | 2022-2025 | Azstarys, Adlarity, Azstarys |
| Janssen Pharmaceuticals, INC | $378.77 | 2019-2025 | Spravato |
| Neurocrine Biosciences, INC. | $375.61 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $336.72 | 2019-2024 | Hetlioz, Fanapt |
| Almatica Pharma LLC | $280.46 | 2021-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $210.14 | 2021-2024 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $197.34 | 2023-2025 | Sunosi, Auvelity |
| Bausch Health US, LLC | $150.63 | 2019-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $138.97 | 2021-2025 | Aristada, Lybalvi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $128.60 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $126.92 | 2019-2022 | |
| Eisai INC. | $126.60 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $125.52 | 2021-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $114.88 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $102.83 | 2021-2024 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $80.14 | 2021-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $77.40 | 2019-2022 | |
| Tris Pharma INC | $73.67 | 2022-2023 | Dyanavel Xr |
| Alfasigma USA, INC. | $58.42 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $40.90 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $40.45 | 2019-2021 | |
| Allergan, INC. | $40.17 | 2019-2020 | |
| Ge Healthcare | $36.44 | 2019 | |
| Neos Therapeutics, LP | $35.17 | 2019-2021 | |
| Lilly USA, LLC | $34.73 | 2022 | |
| Vertical Pharmaceuticals, LLC | $34.42 | 2019 | |
| Noven Pharmaceuticals, INC. | $23.64 | 2021 | |
| Bioxcel Therapeutics, INC. | $18.54 | 2023 | Igalmi |
| Itamar Medical INC | $15.99 | 2024 | Watchpatone |
| Neuronetics, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Steinfink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.